November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment
However, a recent study published in These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy, noted the study authors
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells
The Fast Facts Sweating is great to release toxins and burn calories, but it also discharges electrolytes we need to replenish in our bodies
Higher mean age and baseline SBP, greater use of anti-hypertensive medications, longer T2D duration, and reduction in insulin daily dose might have contributed to explain the difference observed in the impact of weight loss on SBP reduction in these trials, although direct GLP-1R- and GIP-R-mediated effects could also be considered [77]
This program will be delivered through an exclusive coaching app, reserved only for coaching clients